Company intelligence / Profile preview

Saya Bio

Ownership
Private
Development stage
Other
01

Overview

Developing biosimilars for commercialization in Latin America, with partnerships for manufacturing osteoporosis therapies targeted at Mexico.

Therapeutic areas
Endocrinology
Modalities
Biosimilar
Industry
Biotech
02

Drug pipeline

4 assets

RANKL inhibitor biosimilar

Preclinical

3 more assets in the full pipeline.

03

Partnerships

Enzene BiosciencesMaxigen Biotech IncInterfacing Technologies

Beyond the preview

Go deeper on Saya Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saya Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call